Long-term safety and effectiveness of lisocabtagene maraleucel for Mantle Cell Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the long-term safety and effectiveness of lisocabtagene maraleucel (liso-cel) in patients with relapsed or refractory Mantle Cell Lymphoma (MCL) who have received treatment in a post-marketing setting. Participants must have undergone at least one infusion of liso-cel according to FDA-approved guidelines. The study is observational, meaning it will collect data on patient outcomes without altering their treatment regimen. The goal is to gather real-world evidence on the use of this therapy in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

• Participants must have been treated in the postmarketing setting with at least 1 infusion of lisocabtagene maraleucel (Liso-cel) used for the treatment of Mantle Cell Lymphoma (MCL) according to the FDA-approved indication and dose range (ie, per the US Prescribing Information) and with a product meeting the specifications for commercial release approved in the USA

Exclusion Criteria:

* Participants known to be participating in investigational studies at the time of liso-cel infusion.
* Participants treated with non-conforming CAR T-cell product.

Where it's running

• Center for International Blood and Marrow Transplant Research (CIBMTR)
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Study coordinator: BMS Study Connect Contact Center www.BMSStudyConnect.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Memory-Enhanced CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphoma

  This trial tests memory-enhanced 7×19-THEMIS CAR-T cells in adults with relapsed or refractory large B-cell lymphoma to see how safe they are and whether tumors shrink or disappear.

  Recruiting Phase 1/2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07788118

• Orelabrutinib with Obinutuzumab and Short-Course Venetoclax in Treatment-Naïve Mantle Cell Lymphoma

  This trial tests whether a combo of orelabrutinib, obinutuzumab, and a short course of venetoclax is safe and effective for adults with newly diagnosed mantle cell lymphoma.

  Recruiting at 2 sites Phase 2 The First Affiliated Hospital with Nanjing Medical University · Changzhou, Jiangsu and 1 other locations · NCT07719556

• Rocbrutinib and Lacutoclax in B-cell cancers

  This study tests whether Rocbrutinib plus Lacutoclax can help adults with B-cell malignancies, including CLL/SLL, MCL, DLBCL, FL, WM, who have had prior therapy or are treatment-naïve under specific criteria.

  Recruiting Phase 1/2 Guangzhou Lupeng Pharmaceutical Company LTD. · Tianjin · NCT07609862

• Pirtobrutinib plus rituximab for adults with newly diagnosed indolent mantle cell lymphoma

  This trial will test whether combining pirtobrutinib with rituximab is effective and safe for adults newly diagnosed with indolent mantle cell lymphoma.

  Recruiting at 12 sites Phase 2 Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · Lisbon, Lisbon District and 15 other locations · NCT07285590

• Orelabrutinib with lisaftoclax and rituximab for untreated high-risk mantle cell lymphoma

  This trial will try combining orelabrutinib, lisaftoclax, and rituximab in people with untreated, high-risk mantle cell lymphoma to see if it increases complete remissions and delays progression.

  Recruiting Phase 2 Ruijin Hospital · Shanghai, Shanghai Municipality · NCT07272499

• Pomalidomide with orelabrutinib and zuberitamab for newly diagnosed mantle cell lymphoma

  This study tests whether adding pomalidomide to orelabrutinib and zuberitamab helps people with untreated mantle cell lymphoma become minimal residual disease (MRD) negative after six treatment cycles.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07257510

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.